Zurueck zur Suche

Reporte zur Charge TB3KN

Verknuepft ueber VAERS_ID mit VAERSDATA, Vax und Symptoms

41Reporte angezeigt
0Todesfaelle
3Hospitalisiert
0Lebensbedrohlich
1Bleibende Schaeden
TX 4 IA 4 OH 3 NJ 2 MA 2 MI 2 CA 2 FL 2 NC 2 KY 2 WA 2 CO 1

VAERS 2499303

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge TB3KN

schwer
Staat
MO
Alter
29,0
Geschlecht
M
Eingang
04.11.2022
Impfdatum
04.11.2022
Beginn
04.11.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
IM / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Loss of consciousness

Symptomtext

PATIENT BRIEFLY PASSED OUT AFTER RECEIVING VACCINES. CAME TO WITHIN 30 SECONDS. EMS WAS CALLED AND CAME AND CHECKED PATIENT AND OK HIM TO LEAVE. NO MEDICATIONS OR ANYTHING WAS GIVEN.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Loss of consciousness
Hospital-Tage
-
Labordaten
NONE
Aktuelle Erkrankungen
NONE
Vorgeschichte
NONE
Andere Medikamente
NONE
Allergien
NKDA
Vorherige Impfungen
-

VAERS 2408322

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge tb3kn

schwer
Staat
OH
Alter
20,0
Geschlecht
F
Eingang
11.08.2022
Impfdatum
10.08.2022
Beginn
10.08.2022
Tage bis Beginn
0,0
Dosis
1
Route/Site
IM / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Dizziness Syncope

Symptomtext

Patient became light headed and fainted

Weitere VAERSDATA-Felder
Praegender Schweregrund
Syncope
Hospital-Tage
-
Labordaten
none
Aktuelle Erkrankungen
None
Vorgeschichte
None
Andere Medikamente
Unknown
Allergien
none
Vorherige Impfungen
-

VAERS 2683877

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge TB3KN

moderat
Staat
WI
Alter
20,0
Geschlecht
F
Eingang
20.09.2023
Impfdatum
14.09.2023
Beginn
14.09.2023
Tage bis Beginn
0,0
Dosis
1
Route/Site
IM / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Asthenia Fatigue Headache Lethargy Migraine Pyrexia

Symptomtext

Onset of s/s approx 1800: Migraine, fever 100.5, fatigue, weakness, lethargic. Symptoms persisted throughout the night into next morning. Continues to have daily HA/Migraines without prior hx of HA/migraines.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Migraine
Hospital-Tage
-
Labordaten
None
Aktuelle Erkrankungen
No
Vorgeschichte
Reports previous adverse events post previous vaccines, but not to this severity.
Andere Medikamente
Vitamin B-12, Biotin, Ashwagandha.
Allergien
NKA
Vorherige Impfungen
Recalls minor HA, lethargy post influenza vaccine 2022. Recalls HA, lethargy, fever, N/V, cold sweats, chills, body aches post c

VAERS 2154586

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge TB3KN

moderat
Staat
WY
Alter
32,0
Geschlecht
F
Eingang
28.02.2022
Impfdatum
22.02.2022
Beginn
22.02.2022
Tage bis Beginn
0,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: ja Erholt: unbekannt
Blood creatinine increased Blood potassium Blood pressure increased Chest pain Computerised tomogram Deafness Dizziness Ear discomfort Electrocardiogram normal Eye haemorrhage Eye pain Full blood count Haematocrit Haemoglobin Headache Hypertension Influenza A virus test negative Lymphadenopathy

Symptomtext

Pt. said she encountered the following symptoms an hour and half after receiving her 1st adult Hep B, and TST test (in the other arm). She could not say definitively that she'd had the Hep B series as a child: Nausea, dizziness, severe HA, body aches, malaise, bilateral swollen lymph nodes, jaw pain and stiff neck, left eye pain (burst blood vessel in same), blurred vision-left eye, elevated BP-138/88 (normal 90/75), chest pain/"pounding heart", transient pressure in ears with hearing loss. The symptoms have lessened but have not completely gone away. She is still taking acetaminophen/butalbital/caffeine for severe HA.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Chest pain
Hospital-Tage
-
Labordaten
2/24/22/Urgent Care: CBC/CMP (slightly elevated Creatinine ,Pot, Hgb, Hct and MCH); 2/25/22/Urgent Care: EKG-normal w/hypertension; covid/flu-neg; 2/25/22ER: EKG; CT w/contrast-normal.
Aktuelle Erkrankungen
N/A
Vorgeschichte
MTHFR
Andere Medikamente
Vit D, Vit C, Fiber, Protein Powder
Allergien
Ibu-Stevens-Johnson synd,; stertraline-flushes, diarrhea
Vorherige Impfungen
-

VAERS 2688512

MERCK & CO. INC. · HEP B (RECOMBIVAX HB) · Charge TB3KN

mild
Staat
MI
Alter
52,0
Geschlecht
M
Eingang
29.09.2023
Impfdatum
10.08.2023
Beginn
01.08.2023
Tage bis Beginn
-
Dosis
2
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: ja Disable: unbekannt ER: unbekannt Erholt: unbekannt
Liver function test increased Urticaria

Symptomtext

Urticaria and elevated LFTs

Weitere VAERSDATA-Felder
Praegender Schweregrund
Urticaria
Hospital-Tage
3,0
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2688512

MERCK & CO. INC. · HEP B (RECOMBIVAX HB) · Charge TB3KN

mild
Staat
MI
Alter
52,0
Geschlecht
M
Eingang
29.09.2023
Impfdatum
10.08.2023
Beginn
01.08.2023
Tage bis Beginn
-
Dosis
3
Route/Site
- / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: ja Disable: unbekannt ER: unbekannt Erholt: unbekannt
Liver function test increased Urticaria

Symptomtext

Urticaria and elevated LFTs

Weitere VAERSDATA-Felder
Praegender Schweregrund
Urticaria
Hospital-Tage
3,0
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2416162

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge TB3KN

mild
Staat
CA
Alter
54,0
Geschlecht
F
Eingang
19.08.2022
Impfdatum
11.08.2022
Beginn
12.08.2022
Tage bis Beginn
1,0
Dosis
4
Route/Site
IM / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: ja Erholt: ja
Back pain Diarrhoea Dizziness Fatigue Feeling hot Lip swelling Nausea Nodule Pain

Symptomtext

Received Engerix on 8/11/22. On 8/12/22, began feeling fatigue. on 8/13, began having generalized body aches, diarrhea, light-headed, feeling "hot", nauseated. Felt "nodules" on face with pain to touch, and low back pain. Later in the day, began having bottom lip swelling spreading slightly to top lip.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Back pain
Hospital-Tage
-
Labordaten
Was evaluated in Urgent Care where she was prescribed steroids & atarax
Aktuelle Erkrankungen
unknown, but states just completed antibiotic & sudafed treatment for sinus infection just before receiving vaccination
Vorgeschichte
unknown
Andere Medikamente
unknown
Allergien
allergy to clindamycin
Vorherige Impfungen
-

VAERS 2403016

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge TB3KN

mild
Staat
FL
Alter
54,0
Geschlecht
M
Eingang
05.08.2022
Impfdatum
02.08.2022
Beginn
03.08.2022
Tage bis Beginn
1,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Dizziness Pain in extremity

Symptomtext

On Wednesday afternoon client started with a sore arm. Late afternoon client reports experiencing some dizziness.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Dizziness
Hospital-Tage
-
Labordaten
none performed at this time.
Aktuelle Erkrankungen
N/A
Vorgeschichte
N/A
Andere Medikamente
N/A
Allergien
N/A
Vorherige Impfungen
-

VAERS 2367857

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge TB3KN

mild
Staat
NC
Alter
43,0
Geschlecht
M
Eingang
13.07.2022
Impfdatum
12.07.2022
Beginn
12.07.2022
Tage bis Beginn
0,0
Dosis
2
Route/Site
IM / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Urticaria

Symptomtext

Patient was given HEPATITIS B vaccine in office in his right deltoid. No complaints or concerns until about 30 minutes after immunization. He showed me his right arm and it had 5-6 welps posterior arm and one welps on his left upper arm. No difficulty breathing, swallowing, or shortness of breath noted. Vital signs: 124/84 HR:87 Pulse Ox: 97% on room air Resp:18 No pain Temp: 97.9 oral. Provider evaluated patient and administered benadryl 25mg oral and solumedrol 125mg IM. No complaints noted.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Urticaria
Hospital-Tage
-
Labordaten
n/s
Aktuelle Erkrankungen
see below
Vorgeschichte
Keratocuonus, bilateral Hyperlipidemia, Vitamin D, Chronic fatigue
Andere Medikamente
Prednisolone eye drops Pataday eye drops
Allergien
Sulfa drugs
Vorherige Impfungen
-

VAERS 2301655

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge tb3kn

mild
Staat
KY
Alter
36,0
Geschlecht
F
Eingang
29.05.2022
Impfdatum
26.05.2022
Beginn
27.05.2022
Tage bis Beginn
1,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Pain in extremity Peripheral swelling

Symptomtext

patients arm very swollen and painful from prevnar on right arm, left arm with energix b is also swollen and painful

Weitere VAERSDATA-Felder
Praegender Schweregrund
Pain in extremity
Hospital-Tage
-
Labordaten
undisclosed
Aktuelle Erkrankungen
not disclosed
Vorgeschichte
not disclosed
Andere Medikamente
not disclosed
Allergien
not disclosed
Vorherige Impfungen
-

VAERS 2254827

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge TB3KN

mild
Staat
-
Alter
24,0
Geschlecht
F
Eingang
27.04.2022
Impfdatum
25.04.2022
Beginn
25.04.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Erythema Rash macular Urticaria

Symptomtext

Reaction during 15 min wait had blotching, redness and hives start. Treated with: Solumedrol 125 mg IM at 13:40 pm and AT 13:43 Pm Benadryl 50 mg IM per order of FNP All symptoms resolved after medication and patient discharge to home 14:50 with Husband no further complaints (BP 129/77-88-20 and Pulse ox 99%

Weitere VAERSDATA-Felder
Praegender Schweregrund
Rash macular
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
March 2022 - entered vaers

VAERS 2216131

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge TB3KN

mild
Staat
TX
Alter
56,0
Geschlecht
F
Eingang
05.04.2022
Impfdatum
04.04.2022
Beginn
05.04.2022
Tage bis Beginn
1,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Dysuria Pyrexia

Symptomtext

This patient states she woke up on 4/5/22 to a fever around 2-3am of 100-101 and states she also experienced painful urination around the same time. This patient states she checked her fever again at 8:30 am on the same day and it went down to 99. This patient states she increased her fluid intake which lessened the painful urination but states the painful urination is still present.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Pyrexia
Hospital-Tage
-
Labordaten
none
Aktuelle Erkrankungen
none
Vorgeschichte
Asthma
Andere Medikamente
Takes a multivitamin, prescription antihistamine eye drop, Zyrtec , Tumeric, calcium supplement QD. Singulair and Advair for seasonal allergies prn
Allergien
Latex, citrus
Vorherige Impfungen
-

VAERS 2171259

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge TB3KN

mild
Staat
AL
Alter
26,0
Geschlecht
F
Eingang
10.03.2022
Impfdatum
09.03.2022
Beginn
10.03.2022
Tage bis Beginn
1,0
Dosis
1
Route/Site
IM / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Urticaria

Symptomtext

Hives to lower Right and Left hand. No treatment given monitored. No complaints of SOB, dizziness or abnormal CRT.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Urticaria
Hospital-Tage
-
Labordaten
N/A
Aktuelle Erkrankungen
N/A
Vorgeschichte
N/A
Andere Medikamente
N/A
Allergien
N/A
Vorherige Impfungen
-

VAERS 2113279

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge TB3KN

mild
Staat
PA
Alter
48,0
Geschlecht
F
Eingang
15.02.2022
Impfdatum
31.01.2022
Beginn
31.01.2022
Tage bis Beginn
0,0
Dosis
4
Route/Site
IM / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: ja Disable: ja ER: ja Erholt: unbekannt
Acoustic stimulation tests abnormal Anxiety Deafness unilateral Dizziness Ear, nose and throat examination abnormal Eye pain Hyperacusis Magnetic resonance imaging head abnormal Neuritis cranial Photophobia Sudden hearing loss Taste disorder Tinnitus VIIIth nerve injury Vertigo Vomiting

Symptomtext

01/31/2022 severe tinitus at 11:30 sudden loss of hearing right ear, Lightheaded, dizzy. 02/01/2020 saw ENT specalist Hearing test done, 100% loss of hearing in right ear. Steriod injection done in right ear. 02/01/2022 midnight severe virtigo with vomiting and hypersensitivity to sounds, light, taste, anxiety 02/03/2022 went to Hospital by ambulance 02/04/2022 MRI done, results: neuritis of the 8th cranial nerve. 02/05/2022 left hosptal 02/08/2022 saw ENT specialist, hearing has not come back, virtigo remains, hypersensitivity, right eye pain, severe tinitus. ENT recomends Ophalmology: appointment date 02/16/2022 Nephrology 02/18/2022

Weitere VAERSDATA-Felder
Praegender Schweregrund
Dizziness
Hospital-Tage
3,0
Labordaten
Listed in section 18. above 02/01/2020 ENT prescribed 1 gram 3 times a day for a week of Valcyclovir and 60 Mg of steroid. Hospital was given steroids, meclizine, valium and pain medication. Was told to finish prescribed medication from ENT specialist and follow up with him.
Aktuelle Erkrankungen
Tested postive for covid on 01/06/2022
Vorgeschichte
Post kidney transplant recipient 06/06/2019 Tested positive for Covid 11/10/2020
Andere Medikamente
Levithroxine 150 MG daily/ Evarsus Extended Release 4 MG daily Myfortic 180 MG three pills twice dality prednisone 5 Mg daily Valcyclvir 500 Mg daily Gabapentin 200 Mg daily Cinaccalet 30 Mg daily melitonin 10-40 Mg as needed
Allergien
Codine
Vorherige Impfungen
-

VAERS 2727816

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge TB3KN

gering
Staat
IA
Alter
49,0
Geschlecht
F
Eingang
27.12.2023
Impfdatum
19.12.2023
Beginn
19.12.2023
Tage bis Beginn
0,0
Dosis
2
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Expired product administered

Symptomtext

patient was administered a dose of Engerix-B on 19FDec2023 which had an expiration date of 03Dec2023; This non-serious case was reported by a nurse via call center representative and described the occurrence of expired vaccine used in a 49-year-old female patient who received HBV (Engerix B) (batch number TB3KN, expiry date 03-DEC-2023) for prophylaxis. On 19-DEC-2023, the patient received the 2nd dose of Engerix B. On 19-DEC-2023, an unknown time after receiving Engerix B, the patient experienced expired vaccine used (Verbatim: patient was administered a dose of Engerix-B on 19FDec2023 which had an expiration date of 03Dec2023). The outcome of the expired vaccine used was unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 19-DEC-2023 The nurse reported that a patient was administered a dose of Engerix-B which was already expired. At the time of reporting, the dose had not been repeated. The vaccine administration facility was the same as primary reporter. The reporter consented to follow up. This case had been link with US2023177289, reported by the same reporter.; Sender's Comments: US-GSK-US2023177289:Same reporter

Weitere VAERSDATA-Felder
Praegender Schweregrund
Expired product administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2668741

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge TB3KN

gering
Staat
CO
Alter
17,0
Geschlecht
M
Eingang
09.08.2023
Impfdatum
18.07.2023
Beginn
01.07.2023
Tage bis Beginn
-
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
No adverse event Product administered to patient of inappropriate age

Symptomtext

No adverse event reported to facility, however patient given Engerix-B indicated for 20 years old and older but patient 17 years old at time of vaccination

Weitere VAERSDATA-Felder
Praegender Schweregrund
No adverse event
Hospital-Tage
-
Labordaten
none
Aktuelle Erkrankungen
None
Vorgeschichte
None
Andere Medikamente
None
Allergien
None
Vorherige Impfungen
-

VAERS 2648854

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge TB3KN

gering
Staat
OH
Alter
19,0
Geschlecht
F
Eingang
23.06.2023
Impfdatum
07.01.2023
Beginn
07.01.2023
Tage bis Beginn
0,0
Dosis
1
Route/Site
IM / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
No adverse event Product administered to patient of inappropriate age

Symptomtext

There was NO adverse event reported. The patient presented to the pharmacy requesting a second vaccine of HepB. It was determined she was given Engerix-B 20mcg/ml indicated for 20 years and up. She was 19 at the time of administration on 1-7-2023.

Weitere VAERSDATA-Felder
Praegender Schweregrund
No adverse event
Hospital-Tage
-
Labordaten
na
Aktuelle Erkrankungen
na
Vorgeschichte
na
Andere Medikamente
na
Allergien
na
Vorherige Impfungen
-

VAERS 2644280

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge TB3KN

gering
Staat
KY
Alter
0,8
Geschlecht
M
Eingang
12.06.2023
Impfdatum
12.06.2023
Beginn
12.06.2023
Tage bis Beginn
0,0
Dosis
3
Route/Site
IM / RL
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Incorrect dose administered No adverse event

Symptomtext

Patient received the HepB Adult dose instead of the HepB pediatric dose. As of 5:20pm 6/12/2023 patient had not had any adverse effects according to patient's father.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Incorrect dose administered
Hospital-Tage
-
Labordaten
None
Aktuelle Erkrankungen
None
Vorgeschichte
None
Andere Medikamente
None
Allergien
None
Vorherige Impfungen
-

VAERS 2608121

UNKNOWN MANUFACTURER · VACCINE NOT SPECIFIED (NO BRAND NAME) · Charge TB3KN

gering
Staat
OH
Alter
59,0
Geschlecht
F
Eingang
03.04.2023
Impfdatum
17.03.2022
Beginn
19.03.2022
Tage bis Beginn
2,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: unbekannt
Immunisation reaction

Symptomtext

Adverse effect of other vaccines and biological substances, initial encounter on 2022-03-19.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Immunisation reaction
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
Encounter for screening for diabetes mellitus; Encounter for screening for cholesterol level; Type 2 diabetes mellitus without complications; Obstructive sleep apnea (adult) (pediatric); high blood pressure; Post-acute sequela of COVID-19; Other chest pain; Body mass index [BMI] 34.0-34.9, adult; Perioral dermatitis; rash NOS; Body mass index [BMI] 35.0-35.9, adult; Hypothyroidism, unspecified; Type 2 diabetes mellitus without complications; Vitamin D deficiency, unspecified; Adjustment disorder with depressed mood; Obstructive sleep apnea (adult) (pediatric); high blood pressure; Chest pain, unspecified; Encounter for adult health check-up NOS; Added by load_epic.py; Adjustment disorder with depressed mood; Post-acute sequela of COVID-19; Hypothyroidism, unspecified; Type 2 diabetes mellitus without complications; high blood pressure; Encounter for adult health check-up NOS; Lipoma NOS; Hypothyroidism, unspecified; Type 2 diabetes mellitus without complications; Obstructive sleep apnea (adult) (pediatric); high blood pressure; Chest pain, unspecified; Post-acute sequela of COVID-19; Encounter for adult health check-up NOS; Encounter for screening for malignant neoplasm of colon; Encounter for screening mammogram for malignant neoplasm of breast; Body mass index [BMI] 35.0-35.9, adult
Vorgeschichte
-
Andere Medikamente
ADULT BLOOD PRESSURE CUFF LG KIT
Allergien
-
Vorherige Impfungen
-

VAERS 2585704

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge TB3KN

gering
Staat
-
Alter
23,0
Geschlecht
M
Eingang
22.02.2023
Impfdatum
09.09.2022
Beginn
01.09.2022
Tage bis Beginn
-
Dosis
1
Route/Site
IM / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: unbekannt
Unevaluable event

Symptomtext

n/a

Weitere VAERSDATA-Felder
Praegender Schweregrund
Unevaluable event
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2585702

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge TB3KN

gering
Staat
-
Alter
28,0
Geschlecht
M
Eingang
22.02.2023
Impfdatum
27.07.2022
Beginn
22.02.2023
Tage bis Beginn
210,0
Dosis
UNK
Route/Site
IM / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: unbekannt
Unevaluable event

Symptomtext

N/A

Weitere VAERSDATA-Felder
Praegender Schweregrund
Unevaluable event
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2585662

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge TB3KN

gering
Staat
-
Alter
60,0
Geschlecht
F
Eingang
22.02.2023
Impfdatum
22.08.2022
Beginn
01.08.2022
Tage bis Beginn
-
Dosis
1
Route/Site
IM / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: unbekannt
Unevaluable event

Symptomtext

N/A

Weitere VAERSDATA-Felder
Praegender Schweregrund
Unevaluable event
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2585655

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge TB3KN

gering
Staat
-
Alter
63,0
Geschlecht
M
Eingang
22.02.2023
Impfdatum
22.08.2022
Beginn
01.08.2022
Tage bis Beginn
-
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: unbekannt
Unevaluable event

Symptomtext

N/A

Weitere VAERSDATA-Felder
Praegender Schweregrund
Unevaluable event
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2585648

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge TB3KN

gering
Staat
WA
Alter
42,0
Geschlecht
M
Eingang
22.02.2023
Impfdatum
09.09.2022
Beginn
01.09.2022
Tage bis Beginn
-
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: unbekannt
Unevaluable event

Symptomtext

N/A

Weitere VAERSDATA-Felder
Praegender Schweregrund
Unevaluable event
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2585059

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge TB3KN

gering
Staat
WA
Alter
66,0
Geschlecht
F
Eingang
21.02.2023
Impfdatum
29.10.2022
Beginn
01.10.2022
Tage bis Beginn
-
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Unevaluable event

Symptomtext

N/A

Weitere VAERSDATA-Felder
Praegender Schweregrund
Unevaluable event
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
NAFLD, Rheumatoid arthritis, Type 2 diabetes
Andere Medikamente
Prescriptions: atorvastatin 10 mg oral tablet: 1 tab(s) Oral Daily chlorthalidone 25 mg oral tablet: 1 tab(s) Oral Daily Humira Pen 40 mg/0.4 mL subcutaneous kit (adalimumab): 0.4 mL Subcutaneous Every 2 Weeks hydrocortis
Allergien
NKA
Vorherige Impfungen
-

VAERS 2522326

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge TB3KN

gering
Staat
MA
Alter
-
Geschlecht
F
Eingang
03.12.2022
Impfdatum
23.11.2022
Beginn
23.11.2022
Tage bis Beginn
0,0
Dosis
1
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Overdose Product administered to patient of inappropriate age

Symptomtext

20 mcg dose administered to a 14-year-old; 20 mcg dose administered instead of a 10 mcg; This case was reported by a pharmacist via call center representative and described the occurrence of overdose in a 14-year-old female patient who received HBV (Engerix B adult) (batch number TB3KN, expiry date 3rd December 2023) for prophylaxis. On 23rd November 2022, the patient received the 1st dose of Engerix B adult 20 ?g. On 23rd November 2022, unknown after receiving Engerix B adult, the patient experienced overdose and adult product administered to child. On an unknown date, the outcome of the overdose and adult product administered to child were unknown. Additional Information: GSK receipt date: 23-Nov-2022 Reporter's comment: The dose administrated was 20 mcg not 10 mcg dose. The vaccine administration facility was the same as primary reporter. The reporter agreed to follow-up. Additional supportive information: A dose of Engerix-B vaccine (20 mcg) had been administered to a patient of inappropriate age, which led to overdose and adult product administered to child.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Overdose
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2482483

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge TB3KN

gering
Staat
TX
Alter
0,5
Geschlecht
M
Eingang
19.10.2022
Impfdatum
10.10.2022
Beginn
10.10.2022
Tage bis Beginn
0,0
Dosis
3
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Overdose Product administered to patient of inappropriate age

Symptomtext

6 month old received an adult dose; 6 month old received an adult dose; This case was reported by a nurse via call center representative and described the occurrence of overdose in a 6-month-old male patient who received HBV (Engerix B adult) (batch number TB3KN, expiry date 3rd December 2023) for prophylaxis. On 10th October 2022, the patient received the 3rd dose of Engerix B adult. On 10th October 2022, unknown after receiving Engerix B adult, the patient experienced overdose and adult product administered to child. On an unknown date, the outcome of the overdose and adult product administered to child were unknown. Additional Information: GSK Receipt Date: 10-Oct-2022 Reporter's comment: A nurse reported that the patient received an adult 1 ml dose of Engerix. No symptoms were reported. The reporter consented to follow up. Additional Supportive Information: The 6 months old patient received an adult 1 ml dose of Engerix, which led to overdose and adult product administered to child.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Overdose
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2405348

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge TB3KN

gering
Staat
TX
Alter
5,0
Geschlecht
M
Eingang
09.08.2022
Impfdatum
01.08.2022
Beginn
01.08.2022
Tage bis Beginn
0,0
Dosis
4
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Accidental overdose Extra dose administered Product administered to patient of inappropriate age

Symptomtext

5 YO wasgiven adult dose; 5 YO wasgiven adult dose; 5 YO wasgiven 4th dose; This case was reported by a nurse via call center representative and described the occurrence of accidental overdose in a 5-year-old male patient who received HBV (Engerix B adult) (batch number TB3KN, expiry date 3rd December 2023) for prophylaxis. Co-suspect products included hepatitis B vaccine pre-filled syringe device (Engerix B Pre-Filled Syringe Device) injection syringe for prophylaxis. On 1st August 2022, the patient received the 4th dose of Engerix B adult 1 ml and Engerix B Pre-Filled Syringe Device. On 1st August 2022, unknown after receiving Engerix B adult and Engerix B Pre-Filled Syringe Device, the patient experienced accidental overdose, adult product administered to child and extra dose administered. On an unknown date, the outcome of the accidental overdose, adult product administered to child and extra dose administered were unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 3-Aug-2022 Reporter's comment: The patient was accidentally given an adult dose of Engerix-B for his fourth dose at age of 5 years. The reporter did'nt had anything else to report. The reporter consented to follow up. Additional supportive information: The patient received an adult dose of Engerix B at age of 5 years, which led to the accidental overdose and adult product administered to child. The patient received fourth dose of Engerix B at age of 5 years, which led to Extra dose administered.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Accidental overdose
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2402306

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge TB3KN

gering
Staat
IA
Alter
17,0
Geschlecht
F
Eingang
05.08.2022
Impfdatum
01.12.2002
Beginn
01.12.2002
Tage bis Beginn
0,0
Dosis
4
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Extra dose administered Inappropriate schedule of product administration

Symptomtext

received Engerix-B 4th dose; third dose 7/14/2020, first and second Oct 2002 and Dic 2002 respectively; third dose 7/14/2020, first and second Oct 2002 and Dic 2002 respectively; This case was reported by a nurse via call center representative and described the occurrence of extra dose administered in a 17-year-old female patient who received HBV (Engerix B) (batch number TB3KN, expiry date 3rd December 2023) for prophylaxis. Co-suspect products included HBV (Engerix B) for prophylaxis and HBV (Engerix B) for prophylaxis. Previously administered products included Engerix-B (received 1st dose in October 2002). On 30th June 2022, the patient received the 4th dose of Engerix B. On 14th July 2020, the patient received the 3rd dose of Engerix B. In December 2002, the patient received the 2nd dose of Engerix B. In December 2002, unknown after receiving Engerix B, the patient experienced drug dose administration interval too long. On 14th July 2020, the patient experienced drug dose administration interval too long. On 30th June 2022, the patient experienced extra dose administered. On an unknown date, the outcome of the extra dose administered, drug dose administration interval too long and drug dose administration interval too long were unknown. Additional Information: GSK receipt date: 01-Aug-2022 Reporter's comment: The nurse reported that they had two patients received Engerix-B extra dose by error. The reporter consented to follow-up via email. The case is for 2 of 2 linked patients, reported by same reporter. Additional supportive information: The patient received the 2nd and 3rd dose of Engerix-B later than the recommended interval, which led to lengthening of vaccine schedule. The patient also received 4th dose of Engerix-B, which led to extra dose administered. As the patient received an extra dose of Engerix-B and it was clear that the dose was given by error and intention behind the dose giving was unknown therefore extra dose administered event was coded.; Sender's Comments: US-GSK-US2022113816:Same reporter

Weitere VAERSDATA-Felder
Praegender Schweregrund
Extra dose administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2401067

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge TB3KN

gering
Staat
IA
Alter
22,0
Geschlecht
M
Eingang
04.08.2022
Impfdatum
29.07.2022
Beginn
29.07.2022
Tage bis Beginn
0,0
Dosis
4
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Extra dose administered

Symptomtext

received extra dose by error; This case was reported by a nurse via call center representative and described the occurrence of extra dose administered in a 22-year-old male patient who received HBV (Engerix B) (batch number TB3KN, expiry date 3rd December 2023) for prophylaxis. On 29th July 2022, the patient received the 4th dose of Engerix B. On 29th July 2022, unknown after receiving Engerix B, the patient experienced extra dose administered. On an unknown date, the outcome of the extra dose administered was unknown. Additional Information: GSK receipt date: 01-Aug-2022 Reporter's comment: The nurse had two adult patients that received Engerix-B extra dose by error. The reporter consented to follow-up via email. This case is for 1 of 2 linked patients, reported by same reporter. Additional supportive information: The patient received an extra dose of Engerix-B, which led to extra dose administered. As there is no information regarding the primary vaccination of Engerix therefore Extra dose administered event coded as it was clearly stated by error dose was administered and for the primary vaccination details follow-up query was raised.; Sender's Comments: US-GSK-US2022113819:Same reporter

Weitere VAERSDATA-Felder
Praegender Schweregrund
Extra dose administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2398977

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge TB3KN

gering
Staat
-
Alter
-
Geschlecht
U
Eingang
02.08.2022
Impfdatum
-
Beginn
-
Tage bis Beginn
-
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Product storage error

Symptomtext

Temperature excursion 46.2 degree celsius; This case was reported by a consumer via other manufacturer and described the occurrence of incorrect storage of drug in a patient who received HBV (Engerix B) (batch number TB3KN, expiry date unknown) for prophylaxis. Co-suspect products included HAV (Havrix) (batch number 7YA99, expiry date unknown) for prophylaxis. On an unknown date, the patient received Engerix B and Havrix. On an unknown date, unknown after receiving Engerix B and Havrix, the patient experienced incorrect storage of drug. On an unknown date, the outcome of the incorrect storage of drug was unknown. Additional Information: GSK Receipt Date: 28-Jul-2022 Reporter's Comments: The reporter stated that they had temperature excursion last night it went from a temperature of 46.2 degree Celsius at 7:14, at 9 o clock temperature went back to normal. It was unknown if the vaccine was administered to any patient. The reporter wanted to know if the vaccine still ok. Additional supportive Information: The Havrix and Engerix B stored at temperature of 46.2 degree Celsius, which leads to Incorrect storage of drug.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Product storage error
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2344763

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge TB3KN

gering
Staat
IA
Alter
33,0
Geschlecht
F
Eingang
30.06.2022
Impfdatum
27.06.2022
Beginn
27.06.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Electrocardiogram Immunisation reaction Laboratory test

Symptomtext

Done in Health: Benadryl 25mg tablet, Epi 0.3mg IM, Sent ER. ER per patient: Liquid Benadryl, Fluids, Labs and EKG

Weitere VAERSDATA-Felder
Praegender Schweregrund
Electrocardiogram
Hospital-Tage
-
Labordaten
Unknown
Aktuelle Erkrankungen
None
Vorgeschichte
N/A
Andere Medikamente
None
Allergien
Laundry detergent
Vorherige Impfungen
-

VAERS 2328925

MERCK & CO. INC. · HEP B (RECOMBIVAX HB) · Charge TB3KN

gering
Staat
-
Alter
56,0
Geschlecht
F
Eingang
23.06.2022
Impfdatum
10.06.2022
Beginn
10.06.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Incorrect route of product administration No adverse event

Symptomtext

IM injection given SC route. patient was observed for 45 minutes; no adverse event occurred;

Weitere VAERSDATA-Felder
Praegender Schweregrund
Incorrect route of product administration
Hospital-Tage
-
Labordaten
none
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2632813

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge TB3KN

gering
Staat
NJ
Alter
-
Geschlecht
F
Eingang
22.06.2022
Impfdatum
20.06.2022
Beginn
-
Tage bis Beginn
-
Dosis
UNK
Route/Site
- / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: unbekannt
Expired product administered

Symptomtext

I unintentionally administered a Hepatitis A vaccine that expired on 6/18/22.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Expired product administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
None
Vorgeschichte
None
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2306009

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge tb3kn

gering
Staat
NM
Alter
51,0
Geschlecht
F
Eingang
02.06.2022
Impfdatum
25.05.2022
Beginn
25.05.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
IM / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Overdose

Symptomtext

received 3 doses on 25-MAY-2022; This case was reported by a other health professional via call center representative and described the occurrence of overdose in a 51-year-old female patient who received HBV (Engerix B adult) (batch number tb3kn, expiry date 3rd December 2023) for prophylaxis. Co-suspect products included hepatitis B vaccine pre-filled syringe device (Engerix B Pre-Filled Syringe Device) injection syringe for prophylaxis, HBV (Engerix B adult) (batch number tb3kn, expiry date unknown) for prophylaxis, hepatitis B vaccine pre-filled syringe device (Engerix B Pre-Filled Syringe Device) injection syringe for prophylaxis, HBV (Engerix B adult) (batch number tb3kn, expiry date 3rd December 2023) for prophylaxis and hepatitis B vaccine pre-filled syringe device (Engerix B Pre-Filled Syringe Device) injection syringe for prophylaxis. On 25th May 2022, the patient received Engerix B adult (intramuscular) .5 ml, Engerix B Pre-Filled Syringe Device, Engerix B adult (intramuscular) .5 ml, Engerix B Pre-Filled Syringe Device, Engerix B adult (intramuscular) .5 ml and Engerix B Pre-Filled Syringe Device. On 25th May 2022, unknown after receiving Engerix B adult, Engerix B Pre-Filled Syringe Device, Engerix B adult, Engerix B Pre-Filled Syringe Device, Engerix B adult and Engerix B Pre-Filled Syringe Device, the patient experienced overdose. On an unknown date, the outcome of the overdose was unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 27 May 2022 Reporter's comment: The reporter was an administrator for a clinic who reported that a patient received 3 doses of Engerix B on same day. The reporter consented to follow up. Additional Supportive Information: The patient received 3 doses of Engerix B on same day which led to overdose.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Overdose
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2283273

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge TB3KN

gering
Staat
FL
Alter
47,0
Geschlecht
F
Eingang
18.05.2022
Impfdatum
18.05.2022
Beginn
18.05.2022
Tage bis Beginn
0,0
Dosis
3
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Wrong product administered

Symptomtext

incorrect vaccine administered.Boostrix was erroneously given instead of Engerix

Weitere VAERSDATA-Felder
Praegender Schweregrund
Wrong product administered
Hospital-Tage
-
Labordaten
none
Aktuelle Erkrankungen
none
Vorgeschichte
none
Andere Medikamente
na
Allergien
nka
Vorherige Impfungen
-

VAERS 2265582

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge TB3KN

gering
Staat
TX
Alter
-
Geschlecht
F
Eingang
06.05.2022
Impfdatum
-
Beginn
-
Tage bis Beginn
-
Dosis
2
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Inappropriate schedule of product administration

Symptomtext

received dose of engerix-b only two weeks after the 1st dose; This case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too short in a adult female patient who received HBV (Engerix B) (batch number TB3KN, expiry date 3rd December 2023) for prophylaxis. Co-suspect products included hepatitis B vaccine pre-filled syringe device (Engerix B Pre-Filled Syringe Device) injection syringe for prophylaxis. Concomitant products included HEPATITIS B VACCINE (ENGERIX B). On an unknown date, the patient received the 2nd dose of Engerix B and Engerix B Pre-Filled Syringe Device. On an unknown date, unknown after receiving Engerix B and Engerix B Pre-Filled Syringe Device and an unknown time after receiving ENGERIX B, the patient experienced drug dose administration interval too short. On an unknown date, the outcome of the drug dose administration interval too short was unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 26-APR-2022 Reporter's Comments: The reporter stated that patient received the second dose of Engerix B only two weeks after 1st dose. The reporter gave consent for a follow-up. Additional Supportive Information: The patient received the second dose of Engerix b only two weeks after 1st dose, which led to Drug dose administration interval too short.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Inappropriate schedule of product administration
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
ENGERIX B
Allergien
-
Vorherige Impfungen
-

VAERS 2222559

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge TB3KN

gering
Staat
CA
Alter
19,0
Geschlecht
F
Eingang
08.04.2022
Impfdatum
04.04.2022
Beginn
04.04.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Overdose Product administered to patient of inappropriate age

Symptomtext

19-year-old patient received an adult dose; 19-year-old patient received an adult dose; This case was reported by a nurse via call center representative and described the occurrence of overdose in a 19-year-old female patient who received HBV (Engerix B adult) (batch number TB3KN, expiry date unknown) for prophylaxis. On 4th April 2022, the patient received Engerix B adult. On 4th April 2022, unknown after receiving Engerix B adult, the patient experienced overdose and inappropriate age at vaccine administration. On an unknown date, the outcome of the overdose and inappropriate age at vaccine administration were unknown. Additional Information: GSK receipt date: 05-Apr-2022 Reporter's comment: Nurse reported that a patient received an adult dose of Engerix-B, which led to overdose and inappropriate age of vaccine administration. The reporter consented to follow-up.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Overdose
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2207377

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge TB3KN

gering
Staat
NJ
Alter
43,0
Geschlecht
F
Eingang
30.03.2022
Impfdatum
30.03.2022
Beginn
30.03.2022
Tage bis Beginn
0,0
Dosis
3
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
HIV test Hepatitis viral test Needle issue

Symptomtext

ASSOCIATE HAD A FINGER STICK AFTER VACCINATING A PATIENT. ASSOCIATE WAS TRYING TO ENGAGE SAFETY COVER OVER USED NEEDLE

Weitere VAERSDATA-Felder
Praegender Schweregrund
HIV test
Hospital-Tage
-
Labordaten
ASSOCIATE (PHARMACIST) WHO HAD BEEN GRAZED WITH NEEDLE WENT TO A LAB FOR HEPATITIS AND HIV TESTING. SO DID THE PATIENT WHO WAS VACCINATED.
Aktuelle Erkrankungen
none
Vorgeschichte
none
Andere Medikamente
unknown
Allergien
unknown
Vorherige Impfungen
-

VAERS 2182317

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge TB3KN

gering
Staat
NC
Alter
24,0
Geschlecht
F
Eingang
16.03.2022
Impfdatum
14.03.2022
Beginn
14.03.2022
Tage bis Beginn
0,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Erythema

Symptomtext

10 min after injections there was a localized reaction of redness noted on both arms, more on right side. Pt denied SOB, chest tightness, throat swelling. 50mg benadryl and 125mg Solu-Medrol given. Patient began feeling better and was discharged home with instructions if further difficulty.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Erythema
Hospital-Tage
-
Labordaten
na
Aktuelle Erkrankungen
none
Vorgeschichte
none
Andere Medikamente
na
Allergien
na
Vorherige Impfungen
-

VAERS 2134357

GLAXOSMITHKLINE BIOLOGICALS · HEP B (ENGERIX-B) · Charge TB3KN

gering
Staat
MA
Alter
18,0
Geschlecht
M
Eingang
23.02.2022
Impfdatum
18.02.2022
Beginn
18.02.2022
Tage bis Beginn
0,0
Dosis
3
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: unbekannt
Incorrect dose administered Product administered to patient of inappropriate age Product preparation issue

Symptomtext

Patient was given adult formulation of Energix B instead of pediatric dose.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Incorrect dose administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-